20989 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Calcitonin gene related peptide
Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/V
#2COMPOUNDS FOR USE IN INDUCING MYOCARDIAL PERFUSION RECOVERY
#3METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES
#4METHODS OF TREATING INFLAMMATORY SKIN DISORDERS
#5COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
#6METHODS AND COMPOSITIONS FOR TREATING A MICROBIAL INFECTION
#7PEPTIDES AND COMPOSITIONS FOR TREATMENT OF JOINT DAMAGE
#8Compounds for use in inducing myocardial perfusion recovery
#9VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER
#10COMPOSITIONS AND METHODS FOR MODULATING CGRP SIGNALING TO REGULATE INNATE LYMPHOID CELL INFLAMMATORY RESPONSES
#11NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE
#12Methods and compositions for treating a microbial infection
#13Methods of treating inflammatory skin disorders
#14Methods of treating inflammatory skin disorders
#15Methods of treating inflammatory skin disorders
#16Peptides and compositions for treatment of joint damage
#17Systems and methods for the treatment of symptoms associated with migraines
#18COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES
#19NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATING AN ANTI-CANCER IMMUNE RESPONSE
#20Biomembrane, closed structure with biomembrane characteristics or cellular compartment derived from natural sources and/or self-assembly techniques, preparation method and applications thereof
#21SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES
#22Peptides and compositions for treatment of joint damage
#23Microneedle device having a peptide therapeutic agent and an amino acid and methods of making and using the same
#24Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use
#25Compositions for providing agents that degrade in water
#26Use of CGRP antagonist compounds for treatment of psoriasis
#27Peptides and compositions for treatment of joint damage
#28Pharmaceutical lipid compositions
#29Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
#30Solvent/polymer solutions as suspension vehicles
#31Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
#32Microneedle device having a peptide therapeutic agent and an amino acid, methods of making and using the same
#33Use of CGRP antagonist compounds for treatment of psoriasis
#34Amylin analogues and pharmaceutical compositions thereof
#35Amylin analogues and pharmaceutical compositions thereof
#36Solvent/polymer solutions as suspension vehicles
#37Solvent/polymer solutions as suspension vehicles
#38Polypeptides
#39Polypeptides
#40Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
#41Solvent/polymer solutions as suspension vehicles
#42Solvent/polymer solutions as suspension vehicles
#43CONTROLLED RELEASE CGRP DELIVERY COMPOSITION FOR CARDIOVASCULAR AND RENAL INDICATIONS
#44Methods of treating cancer using the calcitonin-gene related peptide (“CGRP”) receptor antagonist CGRP8-37
#45USE OF CGRP ANTAGONIST COMPOUNDS FOR TREATMENT OF PSORIASIS
#46Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles
#47SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES
#48Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
#49METHOD FOR REDUCING ALLERGEN-INDUCED AIRWAY HYPERRESPONSIVENESS
#50USE OF ORGANIC COMPOUNDS
#51Methods of using cgrp for cardiovascular and renal indications
#52Pharmaceutical lipid compositions
#53METHOD FOR FOSTERING BONE FORMATION AND PRESERVATION
#54Method for fostering bone formation and preservation
#55Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
#56Controlled release CGRP delivery composition for cardiovascular and renal indications
#57Method for fostering bone formation and preservation
#58METHOD FOR FOSTERING BONE FORMATION AND PRESERVATION
#59CGRP peptide antagonists and conjugates
#60TREATMENT OF A WOUND WITH A VASODILATOR
#61Methods for treating irritable bowel syndrome
#62Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
#63Use of neuropeptides for traumatic cartilage injury
#64Methods for manipulating satiety
#65Use of telmisartan for the prevention and treatment of vascular headache
#66Solvent/polymer solutions as suspension vehicles
#67Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
#68Methods of diagnosing small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
#69Method for fostering bone formation and preservation
#70Method for fostering bone formation and preservation
#71Treatment of subnormal bone mineral density
#72Use of telmisartan for the prevention and treatment of vascular headache
#73Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia